Premium Nahrungsergänzungsmittel | artgerecht

Alport Syndrome: Causes, Symptoms and Treatment

Alport syndrome is a rare, inherited kidney disease caused by mutations in collagen type IV genes, leading to progressive kidney failure, hearing loss, and eye abnormalities.

Regular tips about health Regular tips about health

Things worth knowing about "Alport Syndrome"

Alport syndrome is a rare, inherited kidney disease caused by mutations in collagen type IV genes, leading to progressive kidney failure, hearing loss, and eye abnormalities.

What is Alport Syndrome?

Alport syndrome is a rare, hereditary connective tissue disorder that primarily affects the kidneys, ears, and eyes. It was first described in 1927 by the British physician Arthur Cecil Alport. The condition is caused by mutations in genes responsible for producing collagen type IV, an essential structural protein found in the basement membranes of the kidneys, inner ear, and eyes. When this protein is absent or abnormal, these membranes cannot maintain their filtration and structural functions, leading to progressive organ damage over time.

Causes and Genetics

Alport syndrome is caused by mutations in the COL4A3, COL4A4, or COL4A5 genes, which encode the chains of collagen type IV. Depending on which genes are affected, the condition follows different inheritance patterns:

X-linked dominant (XLAS): The most common form, caused by mutations in the COL4A5 gene. Males are typically more severely affected than females.
Autosomal recessive (ARAS): Both copies of COL4A3 or COL4A4 are mutated. Males and females are equally severely affected.
Autosomal dominant (ADAS): A mutation in one copy of COL4A3 or COL4A4 is sufficient to cause disease. This form often has a milder course.

Symptoms

The symptoms of Alport syndrome primarily affect three organ systems:

Kidneys

Hematuria: Blood in the urine, often the first sign, appearing even in childhood.
Proteinuria: Excess protein in the urine, indicating progressive kidney damage.
Chronic kidney disease progressing to end-stage renal failure, often in early adulthood.

Hearing

Sensorineural hearing loss: Hearing impairment that typically begins in childhood or adolescence and worsens over time.

Eyes

Anterior lenticonus: A characteristic cone-shaped protrusion of the lens, which can cause visual disturbances.
Other eye changes such as macular flecks or retinal abnormalities may also occur.

Diagnosis

The diagnosis of Alport syndrome is based on a combination of clinical findings, family history, and specific investigations:

Urinalysis: Detection of blood and protein in the urine.
Kidney biopsy: Electron microscopy reveals characteristic thinning and splitting of the glomerular basement membrane.
Genetic testing: Identification of disease-causing mutations by sequencing the COL4A3, COL4A4, or COL4A5 genes -- now the preferred diagnostic approach.
Audiogram: To assess the extent of hearing loss.
Ophthalmological examination: To detect lens or retinal changes.

Treatment

There is currently no cure that corrects the underlying genetic mutation. Treatment aims to slow disease progression and reduce complications:

Medical Therapy

ACE inhibitors or angiotensin receptor blockers (ARBs): These blood pressure medications reduce pressure within the kidney glomeruli, decrease proteinuria, and have been shown to slow the progression of kidney damage. They are now recommended even in children with hematuria and a relevant family history.
SGLT2 inhibitors: Emerging evidence supports a nephroprotective effect of this drug class, and their use is increasingly recommended.

Renal Replacement Therapy

When end-stage renal failure is reached, dialysis or kidney transplantation becomes necessary. Alport syndrome is one of the most common genetic causes of kidney transplantation in children and young adults.

Additional Measures

Regular hearing aid fitting for those with progressive hearing loss.
Ongoing nephrological and ophthalmological monitoring.
Genetic counseling for patients and their families.

Prognosis

The prognosis depends strongly on the inheritance pattern and biological sex. Males with the X-linked form often develop end-stage renal failure before the age of 30. Females with this form generally have a milder course but can also develop kidney insufficiency over time. Early diagnosis and consistent treatment with ACE inhibitors can significantly delay disease progression.

References

Kashtan CE et al. - Alport Syndrome: A Multi-Faceted Kidney Disease. In: Advances in Chronic Kidney Disease, 2012; 19(2):80-85.
Gross O, Kashtan CE et al. - Alport syndrome: from flawed collagen IV to renal failure. In: Nature Reviews Nephrology, 2021; 17(10):642-657.
Savige J et al. - Expert Guidelines for the Management of Alport Syndrome and Thin Basement Membrane Nephropathy. In: Journal of the American Society of Nephrology, 2013; 24(3):364-375.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.

Most read entries

3 Posts in this encyclopedia category